Skip to main content

Table 3 Treatments administered for castration-resistant prostate cancer

From: Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis

  Overall
(n = 299)
Clinical trial
Participants
(n = 65)
Non-participants
(n = 234)
p
Docetaxel
 N 242 (80.9%) 41 (63.1%) 201 (85.9%) 0.001
 No. cycles 4.0 (2.0–9.0) 7.0 (4.0–12.5) 4.0 (2.0–9.0) 0.003
ARAT agent use
 Pre-chemotherapy     0.502
  Abiraterone 10 (3.3%) 2 (3.1%) 8 (3.4%)  
 Enzalutamide 15 (5.0%) 4 (6.2%) 11 (4.7%)
 Post-chemotherapy     < 0.001
  Abiraterone 23 (7.7%) 13 (20.0%) 10 (4.3%)  
  Enzalutamide 108 (36.1%) 9 (13.8%) 99 (42.3%)
Cabazitaxel 1 (0.3%) 0 (0.0%) 1 (0.4%) 1.000
Radium-223 5 (1.7%) 3 (4.6%) 2 (0.9%) 0.070
  1. Abbreviations: ARAT androgen receptor axis-targeted